Cytek Biosciences Valuation
| CTKB Stock | USD 4.50 0.43 8.72% |
At this time, the firm appears to be undervalued. Cytek Biosciences shows a prevailing Real Value of $5.03 per share. The current price of the firm is $4.5. Our model approximates the value of Cytek Biosciences from analyzing the firm fundamentals such as Current Valuation of 394.1 M, return on equity of -0.0336, and Profit Margin of (0.07) % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Cytek Biosciences' valuation include:
Price Book 1.6668 | Enterprise Value | Enterprise Value Ebitda (133.96) | Price Sales 2.9233 | Forward PE 370.3704 |
Undervalued
Today
Please note that Cytek Biosciences' price fluctuation is relatively risky at this time. Calculation of the real value of Cytek Biosciences is based on 3 months time horizon. Increasing Cytek Biosciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Cytek Biosciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Cytek Stock. However, Cytek Biosciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4.5 | Real 5.03 | Target 6.0 | Hype 4.5 | Naive 4.44 |
The real value of Cytek Stock, also known as its intrinsic value, is the underlying worth of Cytek Biosciences Company, which is reflected in its stock price. It is based on Cytek Biosciences' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Cytek Biosciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Cytek Biosciences helps investors to forecast how Cytek stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cytek Biosciences more accurately as focusing exclusively on Cytek Biosciences' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Cytek Biosciences' intrinsic value based on its ongoing forecasts of Cytek Biosciences' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Cytek Biosciences' closest peers. If more than one evaluation category is relevant for Cytek Biosciences we suggest using both methods to arrive at a better estimate.
Cytek Biosciences Cash |
|
Cytek Revenue by Product
Cytek Biosciences Total Value Analysis
Cytek Biosciences is currently forecasted to have valuation of 394.1 M with market capitalization of 575.39 M, debt of 17.02 M, and cash on hands of 349.89 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Cytek Biosciences fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
394.1 M | 575.39 M | 17.02 M | 349.89 M |
Cytek Biosciences Investor Information
About 64.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.67. Some equities with similar Price to Book (P/B) outperform the market in the long run. Cytek Biosciences recorded a loss per share of 0.11. The entity had not issued any dividends in recent years. Based on the key indicators related to Cytek Biosciences' liquidity, profitability, solvency, and operating efficiency, Cytek Biosciences is not in a good financial situation at this time. It has a very high probability of going through financial hardship in March.Cytek Biosciences Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Cytek Biosciences has an asset utilization ratio of 40.13 percent. This suggests that the Company is making $0.4 for each dollar of assets. An increasing asset utilization means that Cytek Biosciences is more efficient with each dollar of assets it utilizes for everyday operations.Cytek Biosciences Profitability Analysis
Based on Cytek Biosciences' profitability indicators, Cytek Biosciences may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in March. Profitability indicators assess Cytek Biosciences' ability to earn profits and add value for shareholders.Net Loss | First Reported 2020-03-31 | Previous Quarter -5.6 M | Current Value -5.5 M | Quarterly Volatility 5.8 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.46 | 0.5 |
|
|
For Cytek Biosciences profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Cytek Biosciences to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Cytek Biosciences utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Cytek Biosciences's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Cytek Biosciences over time as well as its relative position and ranking within its peers.
Cytek Biosciences Earnings per Share Projection vs Actual
By analyzing Cytek Biosciences' earnings estimates, investors can diagnose different trends across Cytek Biosciences' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Cytek Biosciences is based on EPS before non-recurring items and includes expenses related to employee stock options.Cytek Biosciences Ownership Allocation
Cytek Biosciences holds a total of 127.86 Million outstanding shares. Over half of Cytek Biosciences' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Cytek Biosciences Profitability Analysis
The company reported the previous year's revenue of 200.45 M. Net Loss for the year was (6.02 M) with profit before overhead, payroll, taxes, and interest of 105.23 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Cytek Biosciences' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Cytek Biosciences and how it compares across the competition.
About Cytek Biosciences Valuation
The stock valuation mechanism determines Cytek Biosciences' current worth on a weekly basis. Our valuation model uses a comparative analysis of Cytek Biosciences. We calculate exposure to Cytek Biosciences's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Cytek Biosciences's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 127.8 M | 88.2 M | |
| Pretax Profit Margin | (0.03) | (0.03) | |
| Operating Profit Margin | (0.09) | (0.09) | |
| Net Loss | (0.03) | (0.03) | |
| Gross Profit Margin | 0.50 | 0.46 |
Cytek Biosciences Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 130.6 M | |
| Quarterly Earnings Growth Y O Y | 0.735 | |
| Forward Price Earnings | 370.3704 |
Cytek Biosciences Current Valuation Indicators
Valuation refers to the process of determining the present value of Cytek Biosciences and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Cytek we look at many different elements of the entity such as Cytek's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Cytek Biosciences, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Cytek Biosciences' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Cytek Biosciences' worth.Complementary Tools for Cytek Stock analysis
When running Cytek Biosciences' price analysis, check to measure Cytek Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytek Biosciences is operating at the current time. Most of Cytek Biosciences' value examination focuses on studying past and present price action to predict the probability of Cytek Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cytek Biosciences' price. Additionally, you may evaluate how the addition of Cytek Biosciences to your portfolios can decrease your overall portfolio volatility.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing |